FOXO4-DRI: a clever senolytic that has never been tested in people

FOXO4-DRI is a designed peptide that makes senescent cells, the damaged “zombie” cells that build up with age, kill themselves. In mice it did exactly that: a 2017 paper in Cell reported restored fur, improved fitness and better kidney function in old animals, and the result launched a whole field of senolytic research. The mechanism has since been pinned down, from the founding mouse work to human cells in a dish. What it has never done is reach a person: there is no registered human trial of FOXO4-DRI in any condition.

What it is

Cells that are too damaged to divide safely can enter senescence: they stop dividing but don’t die, and they release inflammatory signals that harm neighbouring tissue. In mice, clearing these cells improves many signs of ageing [1], which has made “senolytic” drugs, ones that selectively kill senescent cells, a busy research area.

In 2017 a team led by Peter de Keizer at Erasmus MC in Rotterdam found that senescent cells survive partly because a protein called FOXO4 binds p53, the cell’s self-destruct switch, and holds it in the nucleus where it can’t trigger cell death [1]. They designed a peptide copy of the part of FOXO4 that grips p53, built it from D-amino acids in reverse order (the “D-retro-inverso” in the name), which makes it resistant to digestion by enzymes, and attached a sequence that helps it enter cells [2]. The peptide competes with FOXO4 for p53, freeing p53 to leave the nucleus and set off apoptosis, but only in cells where FOXO4 is doing that job, which is mainly senescent ones [1].

A 2025 structural study using nuclear magnetic resonance showed where the two actually meet: FOXO4 and FOXO4-DRI both bind a flexible, unstructured stretch of p53 called the transactivation domain [2]. The binding site is real and precisely mapped in human protein.

The human evidence

Human data on FOXO4-DRI do not exist yet. We searched ClinicalTrials.gov in September 2026 and found no registered trial of FOXO4-DRI in any condition [10], and no published human study, case series or pharmacokinetic report in PubMed. That is the honest position, and it is why everything below is animal or cell work, labelled as such.

What the animal and lab work shows

The founding study in mice

The Rotterdam team tested the peptide in three mouse settings [1]. In mice given the chemotherapy drug doxorubicin, it reduced the drug’s damage to tissues. In mice genetically engineered to age fast (XpdTTD/TTD mice) and in naturally aged mice, it restored fur density, improved overall fitness, and improved kidney function. It was well tolerated in the mice at the doses used [1].

Follow-up work from other groups

The human-cell studies are useful because they show the mechanism works in human tissue as well as mouse tissue. The cartilage study is also a reminder that removing senescent cells is not the same as restoring function: the peptide cleared them, but the remaining cells made no better cartilage [5].

Two of these studies looked at human tissue before reaching for the peptide, and those observations are the nearest thing to human data. The Leydig cell work found FOXO4 in human testosterone-producing cells, and reported that in older men the protein had moved into the nucleus, the position where it holds p53, in step with lower testosterone synthesis [3]. The keloid study sequenced single cells from people’s keloid scars and found more senescent fibroblasts, higher levels of the senescence marker p16 and a modified form of p53; the peptide then worked on those scar samples kept alive in the lab [6]. Neither involved giving FOXO4-DRI to a person. Note too that the Leydig cell and sperm studies come from overlapping groups of authors [3,4], so they are not fully independent replications.

An Oregon group used computer modelling of the FOXO4–p53 contact to design new peptides, one of which (ES2) cleared senescent cancer cells in mice [7]. Several of those authors hold a patent on ES2 and belong to a company developing it, which is worth knowing when reading the paper.

A result that cuts the other way

Senolytics aren’t automatically good for every tissue. In a 2023 study in Circulation, a French team removed senescent cells in mouse and rat models of pulmonary hypertension, high blood pressure in the lung arteries, using a genetic method, the drug ABT263, or FOXO4-DRI [8]. Clearing the cells worsened lung blood pressure and vessel remodelling in several models, apparently because it wiped out senescent cells lining the lung blood vessels that were doing a useful job [8]. The authors’ conclusion was that senolytic strategies need checking for their effect on lung vessels.

How far other senolytics have got in people

FOXO4-DRI is sometimes described as if it belonged to a class already proven in humans. It doesn’t. The senolytic approach as a whole has reached people only in small, early studies, and none of them used FOXO4-DRI.

The best-known example is the combination of dasatinib, a leukaemia drug, and quercetin, a plant compound. In the first human test, 14 people with idiopathic pulmonary fibrosis, a scarring lung disease, took the pair three days a week for three weeks, with no placebo group [12]. Walking distance, gait speed and chair-stand times improved; lung function and self-reported health did not change, and there was one serious adverse event [12]. The design, open-label with no control group, means it was a feasibility study rather than evidence of benefit.

That matters for FOXO4-DRI in two ways. It shows the idea of killing senescent cells in people is being tested seriously, by academic groups, with trial registration and safety monitoring. And it shows how far the field still is from knowing whether any senolytic helps human ageing. A peptide that hasn’t yet had its first human dose is further back still.

Safety and side effects reported

No human safety data exist. In mice the founding paper reported the peptide was well tolerated under the conditions tested [1], and none of the follow-up animal studies above report toxicity as a finding. That is the ceiling of what can be said.

Several risks are specific to how FOXO4-DRI works, and none has been tested in people:

• Off-target cell death. The peptide’s selectivity depends on senescent cells relying on FOXO4 more than healthy cells do. That margin has been measured in cells and mice, not in humans.
• Loss of useful senescent cells. Senescent cells help with wound healing and, as the pulmonary hypertension study shows, can protect some tissues [8].
• Immune reaction. It is a synthetic peptide built from D-amino acids, which the body doesn’t normally encounter. Nobody knows how human immune systems respond to repeated doses.
• Product identity. A long peptide built from mirror-image amino acids is hard to make correctly. Material sold outside clinical trials comes with no independent assurance of purity, sterility, endotoxin content or heavy-metal load, and no way to confirm that the sequence in the vial is the sequence on the label.

Legal and regulatory status

FOXO4-DRI is not approved as a medicine anywhere, including the UK, the US and the EU, and it has no registered clinical trial [10]. It is not named on the WADA Prohibited List, but substances with no approval for human use fall under WADA’s S0 category, which bans them at all times [11].

What is still open

• Whether FOXO4-DRI does anything in people at all, and at what dose.
• How long it lasts in human blood, where it goes and how it is cleared.
• Whether its selectivity for senescent cells holds up in human tissue inside a living body.
• Which organs benefit from losing senescent cells and which, like the lung vessels in rodents, might be harmed.
• Whether repeated doses provoke an immune response.
• Whether the protective effect against chemotherapy damage seen in mice would hold in people having cancer treatment, the setting where the original mouse data were strongest, and whether it would interfere with the treatment itself.

What this means

FOXO4-DRI has one of the more elegant mechanisms in the senolytic field. It does not poison senescent cells; it releases a brake and lets them shut themselves down, and that target has now been mapped precisely in human protein [2]. That is a genuine scientific result, and it is why the compound keeps resurfacing. But a mechanism that works in a dish is not the same as a medicine, and nine years of animal and cell work have not produced a single human dose.

Our position is that FOXO4-DRI belongs in a trial, and only in a trial. The founding mouse data — restored fur, improved fitness and kidney function, and protection from chemotherapy damage — are strong enough to justify a properly designed first-in-human study with pharmacokinetic sampling, immune monitoring and organ-specific safety endpoints. Nothing in that record justifies buying it. There is no human dose, no half-life and no clearance data, and no way to know whether the peptide’s selectivity for senescent cells survives in a living human body. The same body of work found the opposite effect in one tissue: clearing senescent cells worsened lung blood pressure in rodent models [8]. A first dose taken outside a trial, without those measurements, is an experiment with one subject and no control.

The strongest argument against that view is the one we hear most: the early dasatinib-plus-quercetin study in lung scarring suggests the wider field is moving, so waiting carries a cost [12]. We think that argument proves less than it looks. That study was open-label, had no placebo group and enrolled 14 people; it is a feasibility signal rather than a benchmark, and it tested drugs with known human pharmacology — which FOXO4-DRI does not have. If the senolytic thesis is sound, and we think it is plausible enough to keep funding, then the field’s next step is FOXO4-DRI’s first clean human dataset, collected by people who will publish the null result as readily as the positive one. That dataset is the thing worth arguing for. It is not for sale.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.